Form 4: Puma Biotechnology Director Sells Shares Under Pre-Arranged Plan

Puma Biotechnology Director Alessandra Cesano sold 27,000 shares of common stock for a weighted average price of $3.367 per share, reducing her direct beneficial ownership to 41,850 shares.

Summary

• Director Alessandra Cesano of Puma Biotechnology, Inc. (PBYI) reported a transaction involving the company's common stock.
• On July 18, 2025, Ms. Cesano sold 27,000 shares of PBYI common stock.
• The shares were sold at a weighted average price of $3.367 per share, with individual transaction prices ranging from $3.34 to $3.41.
• This sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on March 11, 2025.
• Following this transaction, Ms. Cesano directly beneficially owns 41,850 shares of PBYI common stock.

Sentiment

Score: 4

Explanation: The sale of shares by a director, even if pre-scheduled under a 10b5-1 plan, can be interpreted by the market as a neutral to slightly negative signal regarding insider confidence, though the pre-scheduled nature mitigates significant negative implications.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not an opportunistic sale based on new, non-public information.

Negatives

• A director reduced their direct beneficial ownership in the company by selling 27,000 shares.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Director Alessandra Cesano sold 27,000 shares of Puma Biotechnology, Inc. common stock.

Stakeholder Impact

• Shareholders may perceive the director's sale of shares as a neutral to slightly negative signal regarding insider confidence in the company's near-term prospects, although the pre-arranged 10b5-1 plan reduces the speculative impact.

Key Dates

Recommendation

A single insider sale, particularly one executed under a pre-arranged 10b5-1 plan, typically does not warrant a change in investment recommendation without additional context from company performance or broader market trends. It provides transparency but does not inherently signal a fundamental shift in the company's outlook.

Keywords

Puma Biotechnology, PBYI, Alessandra Cesano, Director, Stock Sale, Insider Transaction, Form 4, 10b5-1 Plan